Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua

Federico Narvaez[1,2], Carlos Montenegro[2], Jose Guillermo Juarez[2], José Victor Zambrana[2,3], Karla Gonzalez[2,4], Elsa Videa[2] , Sonia Arguello[2], Fanny Barrios[1,2], Sergio Ojeda[2], Miguel Plazaola[2], Nery Sanchez[2], Daniel Camprubí-Ferrer[5a], Guillermina Kuan[6], Gabriela Paz Bailey[5], Eva Harris[7], Angel Balmaseda[2,4]

[1]Unidad de Infectología, Hospital Infantil Manuel de Jesús Rivera, Ministerio de Salud, Managua, Nicaragua

[2]Sustainable Sciences Institute, Managua, Nicaragua

[3]Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA

[4]Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua

[5]Dengue Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, San Juan, Puerto Rico

[6]Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua

[7]Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA

[a]Current affiliation: ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain

Section: Vector-borne Diseases or Global Health and Neglected Tropical Diseases

Corresponding author: Angel Balmaseda, abalmaseda40@gmail.com

Summary: Dengue, a major public health threat, is a viral infection spread by mosquitoes that can cause a range of symptoms from mild to life-threatening. Our study analyzed 19 years of data from two pediatric studies in children 2 to 17 years of age in Managua, Nicaragua. We aimed to understand how dengue severity varies with different serotypes of dengue virus (DENV1-4) and whether the child had a previous dengue infection. We found that DENV2 and DENV3 caused the most sever disease in children. DENV3 lead to sever outcomes in both primary (first-time) and secondary (repeat) infections, while DENV2 is particularly severe in secondary infections. These findings highlight the importance of a balanced dengue vaccine that can protect against all four virus strains, as current vaccines show varying effectiveness. Our research emphasizes the need for effective prevention and treatment strategies to manage dengue, particularly in regions where the virus is widespread.

Keywords: dengue, serotype, disease severity, immune status, pediatric, Nicaragua

Abstract

Background. Dengue virus, a major global health threat, consists of four serotypes (DENV1-4) that cause a range of clinical manifestations from mild to severe and potentially fatal disease.

Methods. This study, based on 19 years of data from the Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study in Managua, Nicaragua, investigates the relationship of serotype and immune status with dengue severity. Dengue cases were confirmed by molecular, serological, and/or virological methods, and sudy participants 6 months to 17 years old were followed during their hospital stay or as ambulatory patients.

Results. We enrolled a total of 15,266 participants, of whom 3,227 (21%) were positive for DENV infection. Of 2,630 cases with serotype result by RT-PCR, 557 corresponded to DENV1, 992 to DENV2, 759 to DENV3 and 322 to DENV4. Severe disease was more prevalent among secondary DENV2 and DENV4 cases, while similar disease severity was observed in both primary and secondary DENV1 and DENV3 cases. According to the 1997 World Health Organization (WHO) severity classification, both DENV2 and DENV3 caused a higher proportion of severe disease compared to other serotypes, whereas DENV3 caused the greatest percentage of severity according to the WHO-2009 classification. DENV2 was associated with increased odds of pleural effusion and low platelet count, while DENV3 was associated with both hypotensive and compensated shock.

Conclusions. These findings demonstrate differences in dengue severity by serotype and immune status and emphasize the critical need for a dengue vaccine with balanced effectiveness against all four serotypes, particularly as existing vaccines show variable efficacy by serotype and serostatus.

Introduction

The four serotypes of dengue virus (DENV1-4), a mosquito-borne *Flavivirus*, affect tens of millions of people worldwide [1]. In recent decades, dengue epidemics have consistently increased in tropical and subtropical regions of the world, with vector control as the principal means of prevention due to the lack of an effective, widely used vaccine. Dengue viruses cause a range of clinical manifestations, from mild to severe and potentially fatal [2]. Understanding the contribution of serotype and immune status (primary versus secondary DENV infection) to clinical spectrum and severe disease is important for developing effective prevention and control strategies, particularly when introducing new vaccines with differential efficacy [3,4].

Developing a dengue vaccine has been challenging, primarily because it needs to provide protection against all four DENV serotypes, as imbalanced protection may result in antibody-dependent enhancement of infection and disease [5,6]. The two approved dengue vaccines vary in efficacy by serotype and immune status. Specifically, Dengvaxia® shows low efficacy for DENV2 and results in increased risk of hospitalization when administered to DENV-naïve recipients [7]; QDenga® has low efficacy againt DENV3 in dengue-naïve children and unknown efficacy against DENV4 [8]. Thus, understanding how dengue severity is modulated by serotype and immune status is critical for public health policy makers. Several studies have addressed this question, most using the 1997 World Health Organization (WHO) severity classification, with only a handful using the 2009 WHO definitions for severe dengue (SD) [9–13]. These studies showed that both DENV2 and DENV3 are associated with the greatest clinical severity [10,14–17]. A previous analysis of our hospital-based study in Nicaragua also showed that DENV2 cases had a higher frequency of shock and internal hemorrhage when compared to DENV1 cases [18]. However, a comprehensive understanding of how dengue severity varies by serotype and immune status remains limited, especially in Latin America compared to other regions like Southeast Asia [10,15–17].

For the past 19 years, we have conducted studies on the diagnosis, classification, and clinical management of dengue in Managua, Nicaragua [18–23]. Here we describe the clinical features and severity of dengue cases stratified by serotype and immune status in almost 3,000 patients presenting to our study health center or hospital and followed over the entire course of illness. We analyze primary and secondary cases of all four DENV serotypes classified by both the 1997 and 2009 WHO guidelines.

Methods

Study design. We leveraged two ongoing studies in Managua: the Pediatric Dengue Cohort Study (PDCS; 2004 to present) and the Pediatric Dengue Hospital-based study (PDHS; 2005 to present). The PDCS is the longest ongoing prospective dengue cohort study, currently in its 20th year, following ~4,000 children aged 2-17 years old (y/o) in a community-based context, with enhanced passive surveillance at the Health Center Sócrates Flores Vivas (HCSFV) in District 2 of Managua [24]. To maintain the age structure of the PDCS, 200-300 new 2-y/o children are enrolled every year, along with an additional ~200 children 3-7 y/o to compensate for loss to follow-up [24]. The PDHS is a clinical study that enrolls patients every year during the dengue season at the Hospital Infantil Manuel de Jesus Rivera (HIMJR), Nicaragua's national pediatric reference hospital. The PDHS enrolls children from 6 months to 14 y/o with symptoms and signs

99 suggestive of an arbovirus infection (WHO 1997) [25] either in the emergency room or in the Infectious
100 Diseases Unit of the HIMJR [20] Children in the PDCS who require hospitalization are referred to the HIMJR,
101 including patients 15-17 y/o. All participants were followed for their entire course of illness. Both the
102 HCSFV and the HIMJR provide free health care services. Here, we present information from patients
103 enrolled in both studies from September 2004 to February 2023.

104 **Classification of dengue disease severity.** Dengue disease severity was defined by the World Health
105 Organization (WHO) guidelines of 1997 (Dengue Fever [DF], Dengue Hemorrhagic Fever [DHF], Dengue
106 Shock Syndrome [DSS]) [25] and 2009 (Dengue without Warning Signs [DwoWS], Dengue with Warning
107 Signs [DwWS] and Severe Dengue [SD]) [2]. See Supplementary Table 1 for more details. Here, we defined
108 severe dengue disease as DHF/DSS (1997) or SD (2009).
109
110 **Laboratory methods and dengue diagnostics.** Cell blood counts (CBC) and blood chemistry tests were
111 conducted using a Cell/Dyn Rubi (Abbot) and Biosystems BA 400 (Biosystems) automated system,
112 respectively, and the trend over time in each patient's platelet and hematocrit values was reviewed.
113 Dengue cases were confirmed by: 1) RT-PCR/viral isolation in acute-phase (days 1-6 post-onset of
114 symptoms) samples and/or 2) seroconversion by DENV IgM MAC-ELISA and/or seroconversion or a ≥4-
115 fold increase in total DENV antibody titers as measured by the Inhibition ELISA (iELISA) in paired sera from
116 the acute and early convalescent phase (14-28 days post-onset of symptoms) [26,27]. Viral RNA was
117 initially detected using a nested or semi-nested RT-PCR [28,29] and later using a multiplex Zika-
118 Chikungunya-Dengue (ZCD) real-time RT-PCR (rRT-PCR) [30] followed by serotyping of DENV-positive by
119 multiplex DENV rRT-PCR [31]. Immune status was determined using iELISA in convalescent samples;
120 <2,560 was considered primary infection and ≥2,560 was considered secondary infection [19,26]. Patients
121 for whom it was not possible to identify the immune response were excluded from the analysis.
122
123 **Statistical methods.** Descriptive statistics were used to summarize demographic and dengue case data
124 from the PDCS and PDHS, yielding participant counts, serotype distribution, and incidence data (see
125 Supplementary Figures for a breakdown of all results by study). Incidence and distribution of infections
126 by serotype and year were calculated. In addition, we analyzed severity by serotype using both the 1997
127 and 2009 WHO classifications, reporting the distribution of primary and secondary DENV infections and
128 the severity classifications by each serotype in raw numbers and percentages. To analyze severity based
129 on the 1997 and 2009 WHO dengue classifications by serotype and immune status, we used marginal
130 effects from multivariate logistic regressions, producing predictive percentages of severe cases by
131 serotype and immune status and applying an interaction term by serotype and immune status, controlling
132 for age and sex.
133
134 We implemented separate logistic regression models adjusting by immune status to calculate the odds
135 ratios of each symptom and sign by serotype, using DENV1 as the reference value. The signs and
136 symptoms comprised a range of clinical indicators including hypotensive shock, compensated shock, poor
137 capillary refill, pleural effusion, hemoconcentration, low platelet counts, mucosal bleeding, intensive care
138 unit (ICU) admission, inotropic drug usage, abdominal pain, vomiting, rash, headache, and myalgia. All

analyses were performed in R version 4.2.2 (R core Team). All the analysis and figures were also stratified by study (PDCS and PDHS) (Supplementary Figures 2-9).

Ethics

The PDCS and PDHS were approved by the Institutional Review Boards of the Nicaraguan Ministry of Health (Protocol #CIRE-09/03/07-008.Ver24 and CIRE-01/10/06-13.ver8, respectively) and the UC Berkeley Committee for the Protection of Human Subjects (Protocols 2010-09-2245 and 2010-06-1649, respectively). Informed consent was obtained from all parents or legal guardians before enrollment; assent was obtained from children 6 years of age and older.

Results

Demographic data and dengue cases. This study includes 15,266 participants, of whom 3,227 were positive for DENV infection. Yearly enrollment (PDHS) or community-based dengue cases (PDCS) varied depending on the epidemic season, with a maximum of 1,751 children in 2019, a minimum of 37 children in 2004, and an average of 101 (Stardard Deviation = 82) children per year combining both studies. Of the 3,227 dengue cases, 2,738 were DENV-positive by RT-PCR. Of these, the immune response was determined in 2,630 patients; only the latter were analyzed. As a result, 557 DENV1, 992 DENV2, 759 DENV3, and 322 DENV4 cases were identified (Table 1). Children were distributed evenly by sex, with 1,290 (50%) females, and the average age of disease onset was 9 years in both studies (PDCS= 9.5 y/o, PDHS= 9.0 y/o) (Table 1). Children were followed throughout the course of disease and were managed as inpatients (mean hospitalization = 4.3 days) or outpatients (mean follow-up = 2.2 days) depending on disease severity. Of the 1,286 DENV-positive participants in the PDCS, 439 (34%) required hospitalization following national guidelines and were transferred to the study hospital.

DENV serotype and immune status. Over the 19 years of the studies, we observed varying patterns of circulating DENV serotypes. DENV2 and DENV3 were the most common serotypes, with predominantly secondary infections for DENV2 and similar numbers of primary and secondary infections for DENV3 (Figure 1). Similar trends were observed in the PDCS and PDHS (Supplementary Figure 1). Interestingly, after 5 years of only DENV2 cases followed by 2 years of COVID-19 travel restrictions, in 2022, we experienced epidemic levels of DENV4 for the first time in 30 years and simultaneous circulation of all four serotypes. Overall, we observed 905 primary infections and 1,725 secondary infections, with primary infections being most frequent in the ages of 6-10 years and secondary infections most prevalent in ages 11-14 years, with an almost equal distribution by sex (Table 2).

Dengue severity by immune status and serotype. The clinical spectrum caused by each serotype was analyzed based on the 1997 and 2009 WHO definitions [2,25]. Using the 1997 classification, 2,212 (84%) patients were DF and 418 (16%) were DHF/DSS (Table 3). Here, severity was defined as DHF/DSS. Using WHO-2009, 1,522 (58%) patients were classified as DwWS and 438 (17%) with SD; therefore, severity was defined as SD (Table 3). Evaluating immune status, we observed that secondary cases were much more prevalent in severe disease caused by DENV2 infections (WHO-1997: 208 [95%] and WHO-2009: 125 [89%]) and DENV4 infections (WHO-1997: 10 [100%] and WHO-2009: 9 [82%]), while for DENV1 (WHO-1997: 27 [64%] secondary and WHO-2009: 50 [59%] secondary) and DENV3 (WHO-1997: 88 [61%] secondary and

181 WHO-2009: 101 [50%] secondary), disease severity was observed in both primary and secondary
182 infections (Table 3, Figure 2). Similar trends were observed in the PDCS and PDHS (Supplementary Figure
183 2). Evaluating by serotype, we found that DENV3 was associated with the greatest severity in both primary
184 and secondary infections according to both 1997 and 2009 WHO classifications, while DENV2 was most
185 associated with DHF/DSS in secondary cases (Table 3 and model-derived estimates compared to DENV1
186 in Figure 3 and Supplementary Figure 3).
187
188 **Clinical signs and symptoms by serotype**. Compared to DENV1, patients with DENV2 had greater odds of
189 ICU admission (Odds Ratio [OR] 2.29, 95% confidence interval [CI]: 1.25-4.51), hemoconcentration
190 (OR=4.86, 2.09-14.20), low platelet count (OR=1.63,1.26-2.12 for <100,000 and OR=2.96, 1.95-4.64 for
191 <50,000), pleural effusion (OR=2.94, 2.18-4.00), and mucosal bleeding (OR=1.53, 1.05-2.28), the last only
192 in secondary infections (Figure 4 and Supplementary Figure 8). We also observed a higher risk of rash
193 (OR=1.82, 1.46-2.28) and fewer cases reporting headache (OR= 0.46, 0.36-0.58) and myalgia (OR=0.71,
194 0.56-0.90) compared to DENV1 (Figure 5). For DENV3, we observed a greater association with general
195 symptoms such as rash (OR=2.96, 2.32-3.77) and myalgia (OR=1.59, 1.25-2.01) and alarm signs such as
196 abdominal pain (OR=2.81, 2.18-3.65) and mucosal bleeding (OR=1.86, 1.39-2.51) (Figure 5). In terms of
197 severity, DENV3 was correlated with pleural effusion (OR=2.49, 1.83-3.43), poor capillary refill (OR=2.08,
198 1.55-2.81), compensated shock (OR=2.31, 1.70-3.19), and hypotensive shock (OR=2.17, 1.45-3.34) (Figure
199 4). See Supplementary Figures 4-9 stratified by immune status and study.
200
201 Severe dengue cases, defined by the WHO-2009 criteria, were primarily characterized by shock. The
202 WHO-2009 definition encompasses both compensated and hypotensive shock, unlike the WHO-1997 DSS
203 definition, which includes only cases with hypotensive shock. Table 4 depicts patients identified upon
204 admission with either compensated or hypotensive shock and those progressing from compensated to
205 hypotensive shock, regardless of medical intervention. Notably, the severity of DENV1 is characterized by
206 compensated shock, with only 12 (14%) of patients progressing from compensated to hypotensive shock,
207 in contrast to DENV2 and DENV3, where more cases presented with hypotensive shock (30 [23%] and 24
208 [12%], respectively) or progressed from compensated to hypotensive shock (42 [33%] or 72 [37%],
209 respectively). Further, other symptoms indicative of plasma leakage, such as pleural effusion and ascites,
210 were higher in DENV2 cases (32% and 40%, respectively) and DENV3 cases (25% and 24%, respectively)
211 compared to DENV1 cases (11% and 13%, respectively) (Figures 4 and 5 and Supplementary Figures 4-9
212 stratified by immune status and study). ICU admission was higher in DENV2 (11%) and DENV3 (8%) cases
213 and lower in DENV1 cases (4%). Laboratory abnormalities such as hemoconcentration and
214 thrombocytopenia were more common in DENV2 (6% and 42%, respectively) and lower in DENV1 (1% and
215 25%) and DENV3 (1% and 29%).
216
217 **Discussion**
218 Dengue virus continues to expand globally, with multiple serotypes co-circulating that cause a wide range
219 of clinical outcomes and can be potentially fatal. To evaluate how disease severity is modulated by
220 immune status and DENV serotype, we leveraged two complementary long-term studies in Nicaragua,
221 including an integrated follow-up system from primary health center to hospital, based on 19 years of
222 data. We used both the 1997 and 2009 WHO severity classification schemes, revealing important

223 distinctions. Overall, we found that DENV2 and DENV3 caused the highest percent of DHF/DSS, and
224 DENV3 caused the highest percent of SD, as well as the greatest number of severe clinical manifestations.
225 DENV2 severity occurred primarily in secondary cases, while DENV3 induced severity in primary and
226 secondary infections. This is consistent with previous publications [9,10,15–17,32–35] and of concern
227 given that currently approved vaccines have poor efficacy against DENV2 for Dengvaxia® and DENV3 for
228 QDenga® vaccines in dengue-naïve recipients [7,8].
229
230 When analyzing immune status by serotype, we found that secondary cases predominated for DENV2 and
231 DENV4, whereas more similar numbers of primary and secondary cases were observed for DENV1 and
232 DENV3, again supported by the literature [18,32,36,37]. Even in younger age groups, DENV2 and DENV4
233 showed a higher percentage of secondary cases, suggesting that primary infections by these serotypes
234 were asymptomatic, consistent with previous reports [9,16,32,38,39]. Likewise, severe disease occurred
235 much more often in secondary DENV2 and DENV4 cases, in contrast to DENV1 and DENV3 severe cases,
236 which were more evenly distributed among primary and secondary cases, as reported elsewhere as well
237 [9,17,36,38–42].
238
239 We analyzed the clinical spectrum of dengue considering the two distinct WHO severity classifications of
240 1997 and 2009. The 1997 definition is more focused on the pathophysiology of vascular leak leading to
241 shock, while the 2009 definition aims for real-time identification of clinical disorders to enable timely case
242 management. The clinical spectrum of dengue using the WHO-1997 definition revealed that most dengue
243 cases evolved as DF, regardless of the serotype involved, with approximately 16% being classified as
244 DHF/DSS. In contrast, using the 2009 classification, only 24% of cases evolved as DwoWS, with the
245 majority as DwWS and 17% classified as SD. Sixty-two percent of the patients classified as DHF/DSS (WHO-
246 1997) were classified as DwWS (WHO-2009). All exhibited a clinical profile characterized by plasma
247 leakage and thrombocytopenia that did not progress to shock or respiratory distress.
248
249 Breaking this down by serotype and immune status, secondary cases showed a higher proportion of WHO-
250 1997 severe disease (DHF/DSS), especially in the case of DENV2 for DSS, while DENV3 had a high
251 proportion of DHF/DSS in secondary cases as well as primary cases. Using the WHO-2009 classification,
252 the serotype that exhibited the highest proportion of SD cases was DENV3 for both primary and secondary
253 infections. Overall, DENV2 was associated with severity using the 1997 classification, whereas DENV3
254 exhibited more severe cases according to both 1997 and 2009 definitions. It is important to note that the
255 WHO-1997 DSS definition includes only cases with hypotensive shock, unlike the WHO-2009 SD definition,
256 which encompasses both compensated and hypotensive shock.
257
258 With respect to clinical signs and symptoms, severe thrombocytopenia (<50,000 platelets) was five times
259 more prevalent in DENV2 than in DENV3 cases. Other markers of severity such as hemoconcentration, a
260 sign of plasma leakage, were more common among DENV2 cases, underscoring the importance of this
261 serotype. Both DENV2 and DENV3 were associated with other signs of plasma leakage, while DENV3 was
262 significantly associated with internal and mucosal bleeding.
263

Of the WHO-2009 SD cases, two-thirds were not classified as severe by WHO-1997, because they failed to meet the full criteria for DHF/DSS. These were predominantly DENV3 cases (50%) followed by DENV1 and DENV2, almost entirely characterized by some form of shock without thrombocytopenia or hemorrhagic manifestations. Interestingly, most severe cases of DENV1 did not progress to hypotensive shock, maintaining only hemodynamic alterations such as poor capillary refill without advancing to hypotension and/or decreased pulse pressure. This is why DENV1 appears to be more severe than DENV2 when applying the 2009 classification. The severity of both DENV2 and DENV3 is characterized by signs of plasma leakage, resulting in ascites and pleural effusion. However, in comparison with DENV1, DENV3 is significantly associated with hemodynamic alterations leading to shock, either in its initial, compensated stage or during the hypotensive phase. Surprisingly, DENV2 did not have this association with shock, whether compensated or hypotensive, when compared to DENV1. This discrepancy may be attributed to a marked difference in the severity of DENV2 when analyzing immune status, where primary cases evolve favorably.

Previous reports have also identified that DENV2 (WHO-1997) and DENV3 (WHO-1997 and WHO-2009) account for the greatest dengue severity [9,15,17,43]. A meta-analysis of 170 global dengue outbreaks from 1990 to 2015 ranked DENV2 as the most frequent cause of outbreaks, followed by DENV1, with DENV3 and DENV4 less commonly reported [44]. Importantly, the mortality rates associated with DENV2 infections were the highest, followed by DENV3, DENV4, and DENV1 rates. These findings suggest that despite their lower frequency, DENV3 outbreaks are associated with significant disease and mortality.

One of the key strengths of our study lies in the comprehensive assessment of dengue severity by serotype, utilizing the two WHO classifications from 1997 and 2009. This aspect is particularly important given that most of the literature on dengue severity utilizes the 1997 classification. The introduction of different serotypes into Nicaragua and their varying impacts on disease severity based on which classification is used highlights the importance of future research presenting results using both classification approaches. Another strength is the longitudinal nature of the study with a large number (almost 3,000) of laboratory-confirmed pediatric dengue cases and a single protocol in place for over almost two decades with consistency of clinical care and data collection. Finally, we analyzed community-based and hospital-based cases, as well as those who progressed from the health center to the hospital – made possible by over a decade of careful work by our physicians harmonizing clinical variables between the two sites and a dedicated team of programmers and data managers creating our customized informatics system and algorithm pipelines.

One limitation of our study was the short circulation time of DENV4, which prevented us from comprehensively analyzing the clinical signs and symptoms of severity in this serotype. Additionally, at the time of this analysis, one lineage of each serotype had circulated in Managua during the study period. Thus, we were not able to compare severity across genotypes or lineages. We plan to expand this analysis following the introduction of new lineages of all the serotypes in 2022 [46].

Overall, our study reveals that DENV2 and DENV3 consistently lead to the highest severity in dengue cases with certain differences according to WHO classification schema. DENV2 primarily impacts secondary

cases, while DENV3 induces severity in primary and secondary infections. These findings highlight the complex interplay between DENV serotypes, immune status and the classifications of disease severity. Moreover, they underscore the need for a vaccine that offers balanced efficacy against all four serotypes.

Notes

Authors contributions. FN, JGJ, GPB, EH, and AB contributed to the conceptualization of the study. FN, GK, and AB supervised the clinical studies. FN, FB, SO, MP, and NS conducted the studies. KG performed laboratory assays. CM and SA curated the data. JVZ, JGJ, DCF and AB analyzed the data. JGJ, JVZ, DCF, EH, and AB generated the initial figures and tables. FN, JGJ, EH, and AB wrote the initial manuscript draft, and DCF and GPB edited the manuscript. All authors reviewed the manuscript for scientific content.

Acknowledgments. We are grateful to Cesar Narvaez for his contribution to data management for the Pediatric Dengue Hospital-based Study. We thank both past and current team members, based at the Hospital Infantil Manuel de Jesús Rivera, Sócrates Flores Vivas Health Center, the Laboratorio Nacional de Virología in the Centro Nacional de Diagnóstico y Referencia, and the Sustainable Sciences Institute in Nicaragua for their commitment and exceptional work. We are deeply grateful to the participants of the Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study and their families.

Financial support. This work was supported by the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) grant numbers P01 AI106695 (EH) and R01 AI099631 (AB). The studies were supported by P01 AI106695 (EH), U01 AI153416 (EH), U19 AI118610 (EH), U54 AI65359 (Barbour; subcontract AB), and BAA-NIAID-DAIT-NIHAI2009061 (Loeb; subcontract AB) from NIAID/NIH, and the the Pediatric Dengue Vaccine Initiative grant VE-1 (EH) and the FIRST grant (EH) from the Bill and Melinda Gates Foundation.

Potential conflicts of interest. The authors declare no conflicts of interest.

Data and materials availability. After securing approval from the UC Berkeley Committee for the Protection of Human Subjects, individual data for figure reproduction can be shared with external researchers. For data access arrangements, please contact E.H. at eharris@berkeley.edu or the CPHS at ophs@berkeley.edu. Standard data transfer agreements govern all data used in this study. The associated code is available at the following link: https://github.com/jgjuarez/Narvaez_Dengue_Clinical_Severity.

Disclaimer. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Centers for Disease Control and Prevention**.**

341 **References**

342 1. Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global variation
343 in dengue transmission intensity. Science Translational Medicine **2020**; 12:eaax4144. Available at:
344 https://www.science.org/doi/10.1126/scitranslmed.aax4144.

345 2. WHO. Dengue guidelines for diagnosis, treatment, prevention and control : new edition. **2009**;
346 Available at: https://apps.who.int/iris/handle/10665/44188.

347 3. de Silva A. Safety of Dengue Vaccine? Clinical Infectious Diseases **2023**; 76:371–372. Available at:
348 https://doi.org/10.1093/cid/ciac690.

349 4. Biswal S, Patel SS, Rauscher M. Safety of Dengue Vaccine? Clin Infect Dis **2022**; 76:771–772.
350 Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938735/.

351 5. Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiology
352 Spectrum **2014**; 2:10.1128/microbiolspec.aid-0022–2014. Available at:
353 https://journals.asm.org/doi/10.1128/microbiolspec.AID-0022-2014.

354 6. de Silva AM, Harris E. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be
355 Concerned about Enhanced Disease after Vaccination? Cold Spring Harb Perspect Biol **2018**;
356 10:a029371. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983190/.

357 7. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and
358 Efficacy. N Engl J Med **2018**; 379:327–340. Available at:
359 https://www.nejm.org/doi/10.1056/NEJMoa1800820.

360 8. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda's Dengue Vaccine
361 Candidate (TAK-003). Clinical Infectious Diseases **2022**; 75:107–117. Available at:
362 https://doi.org/10.1093/cid/ciab864.

363 9. Soo K-M, Khalid B, Ching SM, Chee H-Y. Meta-Analysis of Dengue Severity during Infection by
364 Different Dengue Virus Serotypes in Primary and Secondary Infections. PLOS ONE **2016**; 11.

365 10. Suppiah J, Ching S-M, Amin-Nordin S, et al. Clinical manifestations of dengue in relation to dengue
366 serotype and genotype in Malaysia: A retrospective observational study. PLoS Negl Trop Dis **2018**;
367 12:e0006817. Available at: https://dx.plos.org/10.1371/journal.pntd.0006817.

368 11. Gonçalves BDS, Nogueira RMR, Bispo de Filippis AM, Horta MAP. Factors predicting the severity of
369 dengue in patients with warning signs in Rio de Janeiro, Brazil (1986–2012). Trans Royal Soc Trop
370 Med Hyg **2019**; 113:670–677. Available at: https://doi.org/10.1093/trstmh/trz066.

371 12. Dussart P, Baril L, Petit L, et al. Clinical and Virological Study of Dengue Cases and the Members of
372 Their Households: The Multinational DENFRAME Project. PLoS Negl Trop Dis **2012**; 6:e1482.
373 Available at: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001482.

374 13. Thomas L, Moravie V, Besnier F, et al. Clinical Presentation of Dengue Among Patients Admitted to
375 the Adult Emergency Department of a Tertiary Care Hospital in Martinique: Implications for Triage,
376 Management, and Reporting. Annals Emergency Med **2012**; 59:42–50. Available at:
377 https://www.annemergmed.com/article/S0196-0644(11)01451-X/abstract.

14. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. J Infect Dis **2000**; 181:2–9. Available at: https://doi.org/10.1086/315215.

15. Fried JR, Gibbons RV, Kalayanarooj S, et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis **2010**; 4:e617.

16. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol **2000**; 152:804. Available at: https://doi.org/10.1093/aje/152.9.793.

17. Lovera D, Martínez-Cuellar C, Galeano F, Amarilla S, Vazquez C, Arbo A. Clinical manifestations of primary and secondary dengue in Paraguay and its relation to virus serotype. J Infect Dev Ctries **2019**; 13:1127–1134. Available at: https://jidc.org/index.php/journal/article/view/11584.

18. Balmaseda A, Hammond S, Pérez L, et al. SEROTYPE-SPECIFIC DIFFERENCES IN CLINICAL MANIFESTATIONS OF DENGUE. Am J Trop Med Hyg **2006**; 74:449–456. Available at: https://ajtmh.org/doi/10.4269/ajtmh.2006.74.449.

19. Gutiérrez G, Gresh L, Pérez MÁ, et al. Evaluation of the Diagnostic Utility of the Traditional and Revised WHO Dengue Case Definitions. PLoS Negl Trop Dis **2013**; 7:e2385. Available at: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002385.

20. Narvaez F, Gutierrez G, Pérez MA, et al. Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity. PLoS Negl Trop Dis **2011**; 5:e1397. Available at: https://dx.plos.org/10.1371/journal.pntd.0001397.

21. Hammond SN, Balmaseda A, Pérez L, et al. DIFFERENCES IN DENGUE SEVERITY IN INFANTS, CHILDREN, AND ADULTS IN A 3-YEAR HOSPITAL-BASED STUDY IN NICARAGUA. Am J Trop Med Hyg **2005**; 73:1063–1070. Available at: https://www.ajtmh.org/view/journals/tpmd/73/6/article-p1063.xml.

22. Rocha C, Silva S, Gordon A, et al. Improvement in hospital indicators after changes in dengue case management in Nicaragua. Am J Trop Med Hyg **2009**; 81:287–292.

23. Biswas HH, Ortega O, Gordon A, et al. Early Clinical Features of Dengue Virus Infection in Nicaraguan Children: A Longitudinal Analysis. PLoS Negl Trop Dis **2012**; 6:e1562. Available at: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001562.

24. Kuan G, Gordon A, Avilés W, et al. The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods, Use of Information Technology, and Extension to Other Infectious Diseases. Am J Epidemiol **2009**; 170:120–129. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700880/.

25. WHO, editor. Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control. 2nd ed. Geneva: World Health Organization, 1997.

413 26. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue
414 disease in humans. Science **2017**; 358:929–932. Available at:
415 https://www.science.org/doi/10.1126/science.aan6836.

416 27. Balmaseda A, Sandoval E, Pérez L, Gutiérrez CM, Harris E. Application of molecular typing
417 techniques in the 1998 dengue epidemic in Nicaragua. Am J Trop Med Hyg **1999**; 61:893–897.
418 Available at: https://www.ajtmh.org/view/journals/tpmd/61/6/article-p893.xml.

419 28. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue
420 viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J
421 ClinMicrobiol **1992**; 30:545–551. Available at: https://journals.asm.org/doi/10.1128/jcm.30.3.545-
422 551.1992.

423 29. Harris E, Roberts TG, Smith L, et al. Typing of Dengue Viruses in Clinical Specimens and Mosquitoes
424 by Single-Tube Multiplex Reverse Transcriptase PCR. J Clin Microbiol **1998**; 36:2634–2639. Available
425 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105176/.

426 30. Waggoner JJ, Ballesteros G, Gresh L, et al. Clinical evaluation of a single-reaction real-time RT-PCR
427 for pan-dengue and chikungunya virus detection. J Clin Virol **2016**; 78:57–61. Available at:
428 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836994/.

429 31. Waggoner JJ, Abeynayake J, Sahoo MK, et al. Single-Reaction, Multiplex, Real-Time RT-PCR for the
430 Detection, Quantitation, and Serotyping of Dengue Viruses. PLoS Negl Trop Dis **2013**; 7:e2116.
431 Available at: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002116.

432 32. Balmaseda A, Standish K, Mercado JC, et al. Trends in Patterns of Dengue Transmission over 4 Years
433 in a Pediatric Cohort Study in Nicaragua. J Infect Dis **2010**; 201:5–14. Available at:
434 https://doi.org/10.1086/648592.

435 33. Sasmono RT, Kalalo LP, Trismiasih S, et al. Multiple introductions of dengue virus strains contribute
436 to dengue outbreaks in East Kalimantan, Indonesia, in 2015–2016. Virology J **2019**; 16:93. Available
437 at: https://doi.org/10.1186/s12985-019-1202-0.

438 34. Thomas L, Najioullah F, Besnier F, Valentino R, Césaire JRR, Cabié A. Clinical Presentation of Dengue
439 by Serotype and Year of Epidemic in Martinique. Am J Trop Med Hyg **2014**; 91:138–145. Available
440 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080553/.

441 35. Soe AM, Ngwe Tun MM, Nabeshima T, et al. Emergence of a Novel Dengue Virus 3 (DENV-3)
442 Genotype-I Coincident with Increased DENV-3 Cases in Yangon, Myanmar between 2017 and 2019.
443 Viruses **2021**; 13:1152. Available at: https://www.mdpi.com/1999-4915/13/6/1152.

444 36. Harris E, Videa E, Pérez L, et al. Clinical, epidemiologic, and virologic features of dengue in the 1998
445 epidemic in Nicaragua. Am J Trop Med Hyg **2000**; 63:5–11. Available at:
446 https://www.ajtmh.org/view/journals/tpmd/63/1/article-p5.xml.

447 37. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, et al. Sequential dengue virus infections detected in
448 active and passive surveillance programs in Thailand, 1994–2010. BMC Public Health **2015**; 15:250.
449 Available at: https://doi.org/10.1186/s12889-015-1590-z.

450 38. Yung C-F, Lee K-S, Thein T-L, et al. Dengue serotype-specific differences in clinical manifestation,
451 laboratory parameters and risk of severe disease in adults, singapore. Am J Trop Med Hyg **2015**;
452 92:999–1005. Available at: https://europepmc.org/articles/PMC4426593.

453 39. Zambrana JV, Hasund CM, Aogo RA, et al. Primary exposure to Zika virus is linked with increased
454 risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1. Sci Transl Med
455 **2024**; 16:eadn2199. Available at: https://www.science.org/doi/10.1126/scitranslmed.adn2199.

456 40. BARDE PV, KORI BK, SHUKLA MK, et al. Maiden outbreaks of dengue virus 1 genotype III in rural
457 central India. Epidemiol Infect **2015**; 143:412–418. Available at:
458 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206798/.

459 41. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a
460 prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol **1984**;
461 120:653–669.

462 42. Vuong NL, Quyen NTH, Tien NTH, et al. Dengue viremia kinetics and effects on platelet count and
463 clinical outcomes: An analysis of 2340 patients from Vietnam. eLife **2024**; 13:RP92606. Available at:
464 https://doi.org/10.7554/eLife.92606.

465 43. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic Studies on Dengue in Santiago de Cuba, 1997.
466 Am J Epidemiol **2000**; 152:793–799. Available at: https://doi.org/10.1093/aje/152.9.793.

467 44. Guo C, Zhou Z, Wen Z, et al. Global Epidemiology of Dengue Outbreaks in 1990–2015: A Systematic
468 Review and Meta-Analysis. Front Cell Infect Microbiol **2017**; 7. Available at:
469 https://www.frontiersin.org/articles/10.3389/fcimb.2017.00317.

470

471 **Tables**

472

473

474 **Table 1. Study population: Demographic information, DENV serotype, and health facility, PDCS and**
475 **PDHS, Managua, Nicaragua, 2004-2023.**

	Cohort HC[1] only (n= 847)	Hospital (n= 1,344)	Transferred from cohort HC to Hospital (n=439)
Age	9.61 (SD= 3.60)	9.01 (SD= 3.76)	10.48 (SD= 3.43)
< 1	0 (0%)	31 (2.3%)	0 (0%)
1 to 5	125 (15%)	236 (17%)	43 (10%)
6 to 10	364 (43%)	523 (39%)	162 (37%)
11 to 14	278 (33%)	551 (41%)	185 (42%)
15 to 17	80 (9.5%)	3 (0.2%)	49 (11%)
sexo			
F	441 (52%)	648 (48%)	224 (51%)
Serotype			
DENV1	201 (25%)	268 (20%)	88 (20%)
DENV2	313 (37%)	532 (40%)	147 (33%)
DENV3	182 (21%)	451 (34%)	126 (29%)
DENV4	151 (18%)	93 (6.9%)	78 (18%)

476 [1]Health Center

477

478 **Table 2. Age distribution of dengue cases by DENV serotype and immune status, PDCS and PDHS,**
479 **Managua, Nicaragua, 2004-2023.**

Serotypes	DENV1		DENV2		DENV3		DENV4	
Age group	**1°**	**2°**	**1°**	**2°**	**1°**	**2°**	**1°**	**2°**
< 1	6 (2.1%)	0 (0%)	8 (4.7%)	3 (0.4%)	12 (3.1%)	2 (0.5%)	0 (0%)	0 (0%)
1 to 5	56 (20%)	11 (4.1%)	45 (26%)	93 (11%)	145 (37%)	40 (11%)	6 (10%)	8 (3.0%)
6 to 10	121 (42%)	103 (38%)	79 (46%)	299 (36%)	172 (44%)	171 (46%)	23 (40%)	81 (31%)
11 to 14	100 (35%)	140 (52%)	36 (21%)	389 (47%)	55 (14%)	145 (39%)	17 (29%)	132 (50%)
15 to 17	4 (1.4%)	16 (5.9%)	4 (2.3%)	36 (4.4%)	4 (1.0%)	13 (3.5%)	12 (21%)	43 (16%)
Sex								
F	136 (47%)	128 (47%)	88 (51%)	395 (48%)	194 (50%)	191 (51%)	35 (60%)	146 (55%)
M	151 (53%)	142 (53%)	84 (49%)	425 (52%)	194 (50%)	180 (49%)	23 (40%)	118 (45%)

480

481 **Table 3. Dengue severity by serotype and immune status using the WHO 1997 and 2009**
482 **classifications, PDCS and PDHS, Managua, Nicaragua, 2004-2023.**

Serotypes	DENV1		DENV2		DENV3		DENV4	
	1°	2°	1°	2°	1°	2°	1°	2°
WHO-1997								
DF	272 (95%)	243 (90%)	158 (92%)	612 (75%)	332 (86%)	283 (76%)	58 (100%)	254 (96%)
DHF	12 (4.3%)	21 (7.9%)	12 (7.1%)	160 (20%)	43 (11%)	72 (19%)	0 (0%)	9 (3.5%)
DSS	3 (1.1%)	6 (2.3%)	2 (1.2%)	48 (5.9%)	13 (3.4%)	16 (4.3%)	0 (0%)	1 (0.4%)
WHO-2009								
DWoWS	96 (35%)	89 (34%)	68 (40%)	106 (13%)	71 (18%)	76 (21%)	27 (48%)	102 (40%)
DWW	145 (53%)	126 (48%)	85 (51%)	586 (72%)	214 (56%)	193 (52%)	26 (46%)	147 (57%)
SD	35 (13%)	50 (19%)	15 (8.9%)	125 (15%)	100 (26%)	101 (27%)	3 (5.4%)	9 (3.5%)

483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505

506 **Table 4. Compensated shock and hypotensive shock by DENV serotype.**

Serotype	Only compensated shock	Only hypotensive shock	Hypotensive from compensated shock
DENV1	52 (62%)	20 (24%)	12 (14%)
DENV2	56 (44%)	30 (23%)	42 (33%)
DENV3	97 (50%)	24 (12%)	72 (37%)
DENV4	2 (22%)	6 (67%)	1 (11%)

507

508 **Figure Legends**
509
510 **Figure 1. DENV circulation by immune status in the PDCS and PDHS combined, Managua, 2004-2022**.
511 Circulating serotypes and immune status in dengue cases in the studies in Managua are represented. The
512 hospital study was not run in 2020 and 2021.
513
514 **Figure 2. Distribution by immune response among severe dengue cases, PDCS and PDHS combined,**
515 **Managua, 2004-2022.**
516
517 **Figure 3. Model-derived severity by DENV serotype of infection and immune status in the PDCS and**
518 **PDHS combined, Managua, 2004-2022.** Model-derived estimates compared to DENV1 stratified by WHO
519 disease severity classification and immune status, as indicated. Model was adjusted by age and sex. Due
520 to sample size, DENV4 was excluded from the analysis. Blue dotted line, DENV1 reference value. IR,
521 immune response.
522
523 **Figure 4. Clinical signs, clinical laboratory results, and case management of dengue severity by serotype**
524 **in both primary and secondary cases in the PDCS and PDHS combined, Managua, 2004-2022.** Mucosal
525 bleeding: epitaxis, gingivorrhagia, conjunctival bleeding, hematuria, hematemesis, melena, vaginal
526 bleeding. ICU, intensive care unit.
527
528 **Figure 5. Symptoms of dengue by serotype in both primary and secondary cases in the PDCS and PDHS**
529 **combined, Managua, 2004-2022**.
530

Figure 1


Dengue positive cases
400
200
0
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Years
Serotype
DENV1-P
DENV1-S
DENV2-P
DENV2-S
DENV3-P
DENV3-S
DENV4-P
DENV4-S

533 **Figure 2**



534
535

536 **Figure 3**



537
538

539 **Figure 4**

Clinical variable	Serotype	Events	Observations	Percentage (%)	OR (95% CI)	p value
Hypotensive shock	DENV1	33	557	5.92		
	DENV2	72	992	7.26	1.16 (0.75 to 1.82)	
	DENV3	97	759	12.78	2.17 (1.45 to 3.34)	***
	DENV4	7	322	2.17	0.36 (0.14 to 0.78)	*
Compensated shock	DENV1	65	557	11.67		
	DENV2	98	992	9.88	0.76 (0.54 to 1.08)	
	DENV3	170	759	22.40	2.31 (1.70 to 3.19)	***
	DENV4	3	322	0.93	0.06 (0.01 to 0.17)	***
Pleural effusion	DENV1	63	557	11.31		
	DENV2	316	992	31.85	2.94 (2.18 to 4.00)	***
	DENV3	189	759	24.90	2.49 (1.83 to 3.43)	***
	DENV4	17	322	5.28	0.38 (0.21 to 0.64)	***
Ascitis	DENV1	47	353	13.31		
	DENV2	266	674	39.47	3.36 (2.37 to 4.85)	***
	DENV3	137	564	24.29	1.95 (1.36 to 2.84)	***
	DENV4	14	171	8.19	0.50 (0.26 to 0.93)	*
Poor capillary refill	DENV1	81	518	15.64		
	DENV2	132	892	14.80	0.86 (0.63 to 1.18)	
	DENV3	179	647	27.67	2.08 (1.55 to 2.81)	***
	DENV4	11	322	3.42	0.17 (0.09 to 0.32)	***
Hemoconcentration	DENV1	5	557	0.90		
	DENV2	55	992	5.54	4.86 (2.09 to 14.20)	***
	DENV3	8	759	1.05	1.09 (0.36 to 3.65)	
	DENV4	5	322	1.55	1.52 (0.41 to 5.58)	
Platelets < 100,000	DENV1	114	459	24.84		
	DENV2	416	985	42.23	1.63 (1.26 to 2.12)	***
	DENV3	211	724	29.14	1.25 (0.95 to 1.65)	
	DENV4	48	242	19.83	0.54 (0.36 to 0.80)	**
Platelets < 50,000	DENV1	27	459	5.88		
	DENV2	197	985	20.00	2.96 (1.95 to 4.64)	***
	DENV3	46	724	6.35	1.03 (0.63 to 1.71)	
	DENV4	8	242	3.31	0.42 (0.18 to 0.91)	*
Mucosal and internal bleeding	DENV1	78	557	14.00		
	DENV2	182	992	18.35	1.19 (0.89 to 1.62)	
	DENV3	181	759	23.85	1.86 (1.39 to 2.51)	***
	DENV4	15	322	4.66	0.27 (0.14 to 0.46)	***
ICU	DENV1	13	301	4.32		
	DENV2	62	578	10.73	2.29 (1.25 to 4.51)	*
	DENV3	38	500	7.60	1.84 (0.98 to 3.67)	.
	DENV4	6	152	3.95	0.79 (0.27 to 2.07)	
Inotropic drugs	DENV1	4	308	1.30		
	DENV2	14	640	2.19	1.39 (0.48 to 5.08)	
	DENV3	19	507	3.75	2.51 (0.92 to 8.78)	



540
541
542

543 **Figure 5**

Clinical variable	Serotype	Events	Observations	Percentage (%)	OR (95% CI)	p value
Vomiting	DENV1	142	557	25.49		
	DENV2	253	992	25.50	0.98 (0.76 to 1.25)	
	DENV3	233	759	30.70	1.37 (1.07 to 1.76)	*
	DENV4	81	322	25.16	0.90 (0.65 to 1.24)	
Abdominal pain	DENV1	109	554	19.68		
	DENV2	257	989	25.99	1.28 (0.99 to 1.67)	.
	DENV3	316	758	41.69	2.81 (2.18 to 3.65)	***
	DENV4	62	322	19.25	0.90 (0.63 to 1.28)	
Myalgia	DENV1	192	546	35.16		
	DENV2	274	988	27.73	0.71 (0.56 to 0.90)	**
	DENV3	311	733	42.43	1.59 (1.25 to 2.01)	***
	DENV4	126	321	39.25	1.01 (0.75 to 1.35)	
Headache	DENV1	391	545	71.74		
	DENV2	531	985	53.91	0.46 (0.36 to 0.58)	***
	DENV3	509	734	69.35	1.01 (0.79 to 1.30)	
	DENV4	249	322	77.33	1.17 (0.84 to 1.63)	
Rash	DENV1	303	557	54.40		
	DENV2	666	992	67.14	1.82 (1.46 to 2.28)	***
	DENV3	591	759	77.87	2.96 (2.32 to 3.77)	***
	DENV4	152	322	47.20	0.79 (0.60 to 1.05)	



544
545